Bionor granted up to NOK 10.3 million from Research Council of Norway to further advance Vacc-4x in a combination treatment regimen
(Oslo, Norway, 27 January 2017) Bionor Pharma AS, a wholly owned subsidiary of Solon Eiendom ASA (OSE:SOLON) announces today that the Research Council of Norway (RCN) through its BIA Program (Brukerstyrt Innovasjonsarena), has awarded the company up to NOK 10.3 million to partially fund an exploratory Phase I/II trial of Vacc-4x in combination with an immune regulating agent and a neutralizing antibody.
Bionor’s strategy is to maintain value of the existing IP property related to Vacc-4x in combination with other medicines in order to significantly contribute to a functional HIV cure, and has, as a first step, adopted a “Shock & Kill” clinical strategy employing Vacc-4x (“Kill”) as a core treatment in combination with a latency reversing agent (“Shock”). Bionor anticipates that an immune regulating agent will also be needed as part of a triple regimen combination treatment, to achieve functional cure.
The aim of the project is to carry out a phase I/II clinical study in HIV positive participants, sequentially combining Vacc-4x with a broadly neutralizing antibody (bNab), to determine safety, and the effect on viral reservoirs and plasma viral load during latency reversal using romidepsin while on antiretroviral therapy.